Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
2023年10月25日 - 8:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that new data on the anti-inflammatory and
anti-fibrotic properties of pemvidutide from its 24-week Phase 1b
randomized, placebo-controlled study in subjects with non-alcoholic
fatty liver disease (NAFLD) will be presented in a late-breaking
poster presentation at The Liver Meeting® 2023 of the American
Association for the Study of Liver Diseases (AASLD) in Boston, MA
(November 10-14, 2023). Pemvidutide is a novel, investigational,
peptide-based GLP-1/glucagon dual receptor agonist in development
for the treatment of obesity and non-alcoholic steatohepatitis
(NASH).
Details for the presentation are as follows:
Title: |
Pemvidutide-induced liver fat reduction in subjects with
non-alcoholic fatty liver disease correlate with improvements in
non-invasive markers of inflammation and fibrosis: Results of a
24-week multicenter, randomized, double-blind, placebo-controlled
trial |
Presenter: |
Dr. Stephen Harrison, Medical Director, Pinnacle Research, and
Adjunct Professor of Medicine, Oxford University |
Date/Time: |
Late Breaking Poster Session, Monday, November 13, 2023, at 1:00 pm
EST |
The late-breaking poster will be made available on the Events
section of the Altimmune website at the time of the
presentation.
About Pemvidutide Pemvidutide is a novel,
investigational, peptide-based GLP-1/glucagon dual receptor agonist
in development for the treatment of obesity and NASH. Activation of
the GLP-1 and glucagon receptors is believed to mimic the
complementary effects of diet and exercise on weight loss, with
GLP-1 suppressing appetite and glucagon increasing energy
expenditure. Glucagon is also recognized as having direct effects
on hepatic fat metabolism, leading to rapid reductions in levels of
liver fat. Pemvidutide incorporates the EuPort™ domain, a
proprietary technology that increases its serum half-life for
weekly dosing while likely slowing the entry of pemvidutide into
the bloodstream, which may improve its tolerability.
About AltimmuneAltimmune is a clinical-stage
biopharmaceutical company focused on developing innovative
next-generation therapeutics for the treatment of patients with
liver diseases and obesity. The Company’s lead product candidate,
pemvidutide, is a GLP-1/glucagon dual receptor agonist that is
being developed for the treatment of obesity and NASH. In addition,
Altimmune is developing HepTcell™, an immunotherapeutic designed to
achieve a functional cure for chronic hepatitis B. For more
information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor Contact:Richard EisenstadtChief
Financial OfficerPhone: 240-654-1450reisenstadt@altimmune.com
Media Contact:Danielle CanteyEvoke CanalePhone:
619-826-4657danielle.cantey@evokegroup.com
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 4 2024 まで 5 2024
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 5 2023 まで 5 2024